Sante Ventures

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating cells responsible for driving diseases. Utilizing a unique cytotoxicity-targeting chimera platform, Solu Therapeutics focuses on oncology and also addresses inflammatory and autoimmune diseases. By targeting these disease-driving cells, the company's approach seeks to assist medical professionals in reducing the risks associated with various oncological conditions, ultimately improving patient outcomes and advancing therapeutic options in the healthcare sector.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Developer of a secure collaboration platform designed to create secure data access to support impactful algorithm validation and development. The company's platform supports end-to-end data and algorithm encryption that ensures data security, it uses primary data from the source rather than synthetic or de-identified data, eliminates the risk of data exfiltration and interrogation of the algorithm IP from insiders and third parties, and acts as the middleman and matchmaker between data stewards and algorithm developers, helping healthcare organizations in keeping their data secure in their private cloud infrastructure.

Surgical Safety Technologies specializes in providing data-driven artificial intelligence technology to hospitals, aimed at enhancing surgical safety. The company’s platform offers an objective assessment of both technical and non-technical skills of surgeons, utilizing academically validated frameworks. By delivering descriptive, predictive, and prescriptive insights, the platform supports data-driven clinical and operational decisions, ultimately improving surgical quality and patient safety in healthcare settings.

Wave Life is a new kind of mental health platform that makes emotional wellbeing an achievable part of everyday life. The app's mental health coach and toolkit empower users to live each day with intention. Mental health coaching helps to build self-awareness, discover values, and cope with stress.

ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.

Sensorium Therapeutics is a drug discovery platform based in Boston, Massachusetts, that focuses on developing novel FDA-approved psychoactive medicines. Founded in 2021, the company utilizes an artificial intelligence product engine to discover and develop drugs targeting central nervous system diseases. By integrating historical human efficacy data from natural compounds, Sensorium Therapeutics aims to create new medicines characterized by innovative pharmacology and improved clinical success rates. This approach enables pharmaceutical companies to enhance their drug development processes effectively.

RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Reimagine Care is a healthcare company focused on enhancing community-based oncology care through technology-enabled services. Established in 2020 and based in Nashville, Tennessee, the company seeks to improve the affordability, accessibility, and patient-centricity of cancer care. By collaborating with healthcare systems and independent oncology practices, Reimagine Care supports value-based oncology care delivery. Their approach involves providing the necessary personnel, processes, and a comprehensive technology platform that facilitates the effective and scalable delivery of high-quality cancer care at various locations, including patients' homes. This model aims to enable patients to receive treatment and supportive care in a more convenient and cost-effective manner.

Access Optics specializes in the manufacturing of precision and micro-scale optics tailored for applications in tiny cameras and medical equipment, particularly endoscopic devices. The company combines innovative engineering, process development, and optical fabrication with advanced coating technologies to create high-performance optical assemblies and micro-scale surgical imaging products. Designed to withstand extreme pressures, temperatures, and humidity, these products include hermetic seals that enhance the reliability of medical instruments. Access Optics' commitment to pioneering product development and advanced materials solutions has positioned it as a key supplier for leading original equipment manufacturers in sectors such as endoscopy, dermatology, aerospace, and chromatography, ultimately contributing to improved surgical outcomes.

CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.

RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.

Nirogy Therapeutics is a biotechnology company focused on developing innovative small molecules that target cellular transporters to address chronic diseases, including cancer and autoimmune disorders. The company employs a transporter target platform that integrates transporter biology, structural biology, and computational chemistry to understand the underlying mechanisms of these diseases. This approach guides the design and development of new drugs while also informing strategies for patient selection. By advancing small molecules aimed at disrupting metabolic and immune mechanisms within the tumor microenvironment, Nirogy Therapeutics aims to address significant unmet medical needs in oncology and inflammation.

KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.

KelaHealth, Inc. is a company that specializes in developing clinical decision support software tailored for surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering recommendations to mitigate these issues. By harnessing patient data, the platform aims to enhance the quality of surgical care and operational efficiency. It provides patient-specific insights and suggested interventions at critical decision points, creating a learning ecosystem that fosters continuous improvement in surgical outcomes. Additionally, KelaHealth's technology helps standardize practices among surgeons and addresses the administrative and regulatory requirements for quality compliance in surgical operations, ultimately assisting physicians and hospital administrators in better assessing patient risk and enhancing surgical quality.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.

CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.

Glyscend Therapeutics, established in 2014 and headquartered in Baltimore, Maryland, specializes in developing innovative treatments for metabolic diseases, with a primary focus on type 2 diabetes. The company's core product is a non-invasive, orally ingestible intestinal coating that mimics the positive effects of bariatric surgery, preventing the stimulation of duodenal mucosa and inhibiting key neurohormonal pathways in the proximal gut. This approach aims to provide patients with an effective, non-surgical strategy to manage their blood glucose levels, while also reducing potential side effects and offering healthcare providers a new tool to treat, rather than merely manage, the disease.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Remedy provides an on-demand urgent and primary care service focusing on innovative delivery of care. Remedy delivers medical care in the form of 24/7 telemedicine and nurse access, lab visits, and house calls, for individual patients and large employer clients, enabling patients to get quality doorstep treatment at an affordable price. Remedy was founded in 2015 and is based in Austin, Texas.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.

CryOSA is a medical device company focused on developing innovative treatments for obstructive sleep apnea. The company creates devices aimed at assisting patients with sleep-disordered breathing, particularly those experiencing moderate to severe forms of this condition. By addressing the challenges associated with obstructive sleep apnea, CryOSA seeks to improve the quality of life for individuals affected by this disorder.

HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.

Terapio Corporation is a biopharmaceutical company founded in 2005 and based in Austin, Texas. The company specializes in developing therapeutics that utilize the transport protein RLIP76, which plays a crucial role in moving free-radical toxins out of cells, thereby preventing significant cellular damage. Terapio's pipeline includes therapies that enhance the availability of RLIP76 in normal cells, improving their ability to combat toxins from various sources, including chemical exposure and radiation. The therapeutics are designed as medical countermeasures, providing prophylactic and post-exposure treatment options for civilian, military, and first responder populations facing chemical and radiation threats.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Lyric Pharmaceuticals Inc. is a clinical-stage pharmaceutical company founded in 2013 and based in South San Francisco, California. The company focuses on developing novel gastrointestinal therapeutics aimed at addressing unmet medical needs in critically ill and hospitalized patients. One of its primary products, ulimorelin, is a macrocyclic agonist of the hormone ghrelin, being developed as LP101 for the treatment of enteral feeding intolerance and other gastrointestinal disorders in the intensive care unit. Lyric's portfolio includes pro-kinetic and pro-metabolic drugs designed to improve patient care in hospital settings.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Renascent Foundation offers evidence-based, trauma-informed care that addresses drug and alcohol addiction and concurrent mental health issues. They offer specialized addiction support programs for individuals, families, children, workplaces, organizations, and communities impacted by drug and alcohol addictions.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Ketra specializes in high-performance LED lighting and integrated control systems designed for both high-end residential and commercial environments. The company offers a complete range of lighting components, including light fixtures, controls, and software, all manufactured in-house to ensure compatibility and cohesion. This integrated approach facilitates streamlined installation and user-friendly operation. Ketra's innovative technologies focus on delivering natural light experiences that enhance well-being, productivity, and overall quality of life. By providing advanced systems that balance color stability and uniform intensity, Ketra aims to create healthier and happier living and working spaces.

Guided Interventions is a Cleveland-based medical device startup focused on developing innovative wire-based medical devices aimed at enhancing the efficacy and safety of interventional procedures. Led by CEO Dr. Matthew Pollman, the company specializes in a fractional flow reserve (FFR) guidewire that facilitates accurate FFR measurements during coronary catheterization. This device is designed to improve maneuverability and handling, thereby enabling healthcare professionals to assess the physiological impact of coronary artery blockages more effectively. By minimizing the use of stents and reducing the risks associated with heart surgery, Guided Interventions aims to lower costs and improve patient outcomes in the treatment of cardiovascular conditions.

Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.

TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.

Healthcare Highways, Inc. is an accountable care organization and health plan based in Frisco, Texas, founded in 2010 by Michael Wilson. The company collaborates with hospitals, providers, employers, payers, and brokers to offer customized healthcare solutions that aim to reduce costs while maintaining high-quality care. Its services include third-party administration, stop-loss coverage, disease management, pharmacy benefit management, and population health initiatives. With a focus on proactive strategies, Healthcare Highways addresses current and emerging challenges in the healthcare landscape by creating innovative plans tailored to the needs of self-insured clients. The company emphasizes the importance of facilitating a smooth transition for consumers and employers in a complex healthcare environment, ultimately striving to deliver sustainable value and improved healthcare outcomes for all stakeholders involved.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.

Rex Bionics Ltd. is a New Zealand-based company that specializes in the development and manufacturing of robotic medical equipment aimed at rehabilitation. Incorporated in 2007, the company produces the REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Rex Bionics focuses on improving the physical and psychological well-being of people affected by spinal cord injuries, strokes, traumatic brain injuries, and neurodegenerative diseases. The company's primary products include the REX and the REX P (Personal), which cater to both professional neuro-rehabilitation clinics and personal homecare markets. Through innovative technology, Rex Bionics aims to enhance the rehabilitation experience for individuals facing significant mobility challenges.

AbVitro is a biotechnology company based in Boston, Massachusetts, focused on advancing treatments for diseases with immune-related components. The company utilizes high-throughput genomic sequencing to analyze millions of tumor and blood cells, aiming to identify new antigen targets and T-cell receptors for cancer immunotherapies. AbVitro's mission centers on leveraging the human immune system to uncover potential therapeutic targets or biomarkers while discovering fully human antibody binders and T cell receptors to address unmet medical needs in various diseases.

LumaTherm, Inc.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.

Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.

Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.

EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.

Terapio Corporation is a biopharmaceutical company founded in 2005 and based in Austin, Texas. The company specializes in developing therapeutics that utilize the transport protein RLIP76, which plays a crucial role in moving free-radical toxins out of cells, thereby preventing significant cellular damage. Terapio's pipeline includes therapies that enhance the availability of RLIP76 in normal cells, improving their ability to combat toxins from various sources, including chemical exposure and radiation. The therapeutics are designed as medical countermeasures, providing prophylactic and post-exposure treatment options for civilian, military, and first responder populations facing chemical and radiation threats.

Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢

HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢

Protein Discovery, Inc. is a life sciences company specializing in the development and commercialization of innovative sample preparation technologies for protein and peptide analysis via mass spectrometry. The company offers several key products, including the Gelfree 8100 fractionation system, which separates complex protein mixtures into liquid-phase molecular weight fractions, and the Passport 1200 sample preparation system, designed to enrich low molecular weight proteins and peptides while eliminating matrix interferences, facilitating high-throughput quantification. Additionally, Protein Discovery provides the PPS Silent Surfactant, a reagent that solubilizes membrane proteins and reduces detergent interference. The UPX universal protein extraction kit is also available for detergent extraction of proteins from cells and tissues. Catering to life science researchers and drug development scientists, Protein Discovery markets its products both through Agilent Technologies and online, reaching a global audience. Founded in 2001 in Knoxville, Tennessee, the company was originally named Qgenics Biosciences, Inc. before rebranding to its current name in 2004.

Spinal Restoration, Inc. is a company focused on developing early intervention and minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it has created the Biostat System, which is designed to address chronic discogenic pain caused by internal disc disruptions. This system includes a resorbable biologic compound known as BIOSTAT BIOLOGX Fibrin Sealant, which acts as a tissue sealant, and a proprietary delivery device that administers the biologic directly to the intervertebral disc. The Biostat System aims to provide an effective treatment option for the significant population of adults—approximately four million—suffering from chronic low back pain.